TrialBlood advances2020

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.

Sirpa Leppä et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.